- Home
- AIG vs EW Comparison
AIG vs EW Comparison
Compare AIG & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIG | EW |
|---|---|---|
| Founded | 1919 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9B | 49.5B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | AIG | EW |
|---|---|---|
| Price | $73.17 | $84.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 21 |
| Target Price | $87.57 | ★ $96.37 |
| AVG Volume (30 Days) | ★ 5.5M | 3.1M |
| Earning Date | 02-10-2026 | 02-10-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.51 | 2.33 |
| Revenue | ★ $27,120,000,000.00 | $5,883,800,000.00 |
| Revenue This Year | $1.70 | $14.29 |
| Revenue Next Year | $6.64 | $9.68 |
| P/E Ratio | ★ $13.04 | $36.90 |
| Revenue Growth | 2.52 | ★ 10.60 |
| 52 Week Low | $71.74 | $65.94 |
| 52 Week High | $88.07 | $87.89 |
Technical Indicators
Market Signals| Indicator | AIG | EW |
|---|---|---|
| Relative Strength Index (RSI) | 30.32 | 48.32 |
| Support Level | $72.11 | $81.26 |
| Resistance Level | $74.27 | $86.10 |
| Average True Range (ATR) | 1.77 | 1.74 |
| MACD | -1.30 | -0.22 |
| Stochastic Oscillator | 5.90 | 48.87 |
Price Performance
Historical ComparisonAbout AIG American International Group Inc. New
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. The company recently spun off its life insurance operations (Corebridge), but still retains a minority stake.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.